Infliximab treatment in pathology-confirmed neurosarcoidosis

OBJECTIVE: To assess the efficacy and risks of treatment with infliximab (anti–tumor necrosis factor alpha) in pathology-confirmed neurosarcoidosis. METHODS: In a retrospective study in 2 tertiary referral centers in the Netherlands, we analyzed clinical characteristics, complications, and outcome o...

Descripción completa

Detalles Bibliográficos
Autores principales: Fritz, Daan, Timmermans, Wilhelmina M.C., van Laar, Jan A.M., van Hagen, P. Martin, Siepman, Theodora A.M., van de Beek, Diederik, Brouwer, Matthijs C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413716/
https://www.ncbi.nlm.nih.gov/pubmed/32718952
http://dx.doi.org/10.1212/NXI.0000000000000847

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413716/
https://www.ncbi.nlm.nih.gov/pubmed/32718952
http://dx.doi.org/10.1212/NXI.0000000000000847

Ejemplares similares